Dual antiplatelet therapy (DAPT) with aspirin and a platelet P2Y12 receptor inhibitor is the
standard antithrombotic treatment after percutaneous coronary interventions (PCI). Several …

Dual antiplatelet therapy (DAPT) with aspirin plus a P2Y12 inhibitor for 6-12 months is the
current standard treatment for patients after percutaneous coronary intervention (PCI) …

For secondary prevention of coronary artery disease (CAD) antiplatelet therapy is essential.
For patients undergoing a percutaneous coronary intervention (PCI) temporary dual …

Historically, aspirin has been the primary treatment for the prevention of ischaemic events in
patients with coronary artery disease. For patients undergoing percutaneous coronary …

Antiplatelet therapy is considered essential for secondary prevention of ischemic heart
disease. After percutaneous coronary intervention (PCI), temporary dual antiplatelet therapy …

Optimal antiplatelet therapy after percutaneous coronary intervention (PCI) has been
changed in parallel with the improvements of coronary stent and antiplatelet therapy. Over …

Background A number of trials have assessed the efficacy and safety of short-term dual
antiplatelet therapy (DAPT) in patients who undergo percutaneous coronary intervention …

Antiplatelet therapy has a critical role to play in the successful management of patients
undergoing percutaneous coronary intervention (PCI). Over the past 40 years, a multitude of …

Background It is still unknown which antiplatelet monotherapy should be continued after a
period of dual antiplatelet therapy (DAPT) in patients undergoing percutaneous coronary …

For 20 years, dual antiplatelet therapy (DAPT), consisting of the combination of aspirin and a
platelet P2Y12 receptor inhibitor, has been the gold standard of antithrombotic …